09:20 AM EDT, 04/02/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday it has completed its purchase of Intra-Cellular Therapies, adding the schizophrenia and bipolar depression drug Caplyta to its portfolio.

The companies said in January that Johnson & Johnson ( JNJ ) agreed to pay $132 per share in cash for a total equity value of roughly $14.6 billion.

Johnson & Johnson ( JNJ ) said Wednesday the acquisition, which also includes a clinical-stage pipeline, is expected to increase 2025 sales growth by about 0.8%, contributing roughly $0.7 billion in additional revenue.

The company said it expects the deal to reduce 2025 adjusted earnings by about $0.25 per share, an improvement from the previously estimated $0.30 to $0.35 dilution.

In 2026, the expected EPS reduction is projected to narrow to about $0.21, the company added.

The company said it plans to include these estimates in its 2025 financial outlook when it reports Q1 results on April 15.